Protein-truncating variants in BSN are associated with severe adult-onset obesity, type 2 diabetes and fatty liver disease.

Obesity is a major risk factor for many common diseases and has a substantial heritable component. To identify new genetic determinants, we performed exome-sequence analyses for adult body mass index (BMI) in up to 587,027 individuals. We identified rare loss-of-function variants in two genes (BSN and APBA1) with effects substantially larger than those of well-established obesity genes such as MC4R. In contrast to most other obesity-related genes, rare variants in BSN and APBA1 were not associated with normal variation in childhood adiposity. Furthermore, BSN protein-truncating variants (PTVs) magnified the influence of common genetic variants associated with BMI, with a common variant polygenic score exhibiting an effect twice as large in BSN PTV carriers than in noncarriers. Finally, we explored the plasma proteomic signatures of BSN PTV carriers as well as the functional consequences of BSN deletion in human induced pluripotent stem cell-derived hypothalamic neurons. Collectively, our findings implicate degenerative processes in synaptic function in the etiology of adult-onset obesity.

Sequencing of 640,000 exomes identifies GPR75 variants associated with protection from obesity.

Large-scale human exome sequencing can identify rare protein-coding variants with a large impact on complex traits such as body adiposity. We sequenced the exomes of 645,626 individuals from the United Kingdom, the United States, and Mexico and estimated associations of rare coding variants with body mass index (BMI). We identified 16 genes with an exome-wide significant association with BMI, including those encoding five brain-expressed G protein-coupled receptors (CALCR, MC4R, GIPR, GPR151, and GPR75). Protein-truncating variants in GPR75 were observed in ~4/10,000 sequenced individuals and were associated with 1.8 kilograms per square meter lower BMI and 54% lower odds of obesity in the heterozygous state. Knock out of Gpr75 in mice resulted in resistance to weight gain and improved glycemic control in a high-fat diet model. Inhibition of GPR75 may provide a therapeutic strategy for obesity.

Let-7c overexpression inhibits dengue virus replication in human hepatoma Huh-7 cells.

MicroRNAs (miRNAs) constitute an important class of non-coding RNA implicated in gene expression regulation. More than 1900 miRNA molecules have been identified in humans and their modulation during viral infection and it is recognized to play a role in latency regulation or in establishing an antiviral state. The liver cells are targets during DENV infection, and alteration of liver functions contributes to severe disease. In this work the miRNAs expression profile of the human hepatoma cell line, Huh-7, infected with DENV-2 was determined using microarray and real-time PCR. Let-7c is one of the miRNAs up-regulated during DENV infection in the hepatic Huh-7 as well as in the macrophage-monocytic cell line U937-DC-SIGN. Let-7c overexpression down-regulates both DENV-2 and DENV-4 infection. Additionally, we found that the transcription factor BACH1, a let-7c target, is also down-regulated during DENV infection. In accordance with this finding, HO-1, the main responsive factor of BACH1 was found up-regulated. The up-regulation of HO-1 may contribute to the stress oxidative response in infected cells.

HPV-16 and HLA-DRB1 alleles are associated with cervical carcinoma in Mexican Mestizo women.

The aim of this report was to investigate the contribution of HLA-DRB1/DQB1 alleles to the expression of cervical cancer (CC) and squamous intraepithelial lesion (SIL) in Mexican patients. A total of 257 women were included in the study: 61with low-grade squamous intraepithelial lesions (LSIL), 30 with high-grade (HSIL), 73 with CC and 93 healthy females. All were Mexican Mestizos. For HLA class II typing, PCR-SSOP methodology was used. HPV-16 viral DNA was detected by PCR with specific primers for E6-E7 region. HPV-16 was found in 52% of the patients with CC as well as in 19% of women with HSIL and in 12.5% of females with LSIL. HLA-DRB1∗04:03 (OR = 5.88) was found increased in patients with HSIL as compared with controls, although significance (p = 0.04) was lost after correction (pc =NS). HLA-DRB1∗04:03 seems to influence the risk for developing HSIL, disregarding the presence of HPV-16. HLA-DRB1∗01:01 (OR = 0.12; p = 0.01) may confer protection to the development of CC. An analysis performed stratifying by the presence of HPV-16 infection showed that the frequency of HLA-DRB1∗04:07 (OR = 2.71) was increased in CC patients infected with HPV-16, confirming that the HLA association is HPV dependent. These results shed light on the influence that this virus may have in the expression of CC in the susceptible host. Genetic background is, therefore, a crucial factor in understanding the etiopathogenesis of CC in HPV-positive patients.

[Human papilloma virus and cervical cancer]. / Virus del papiloma humano y cáncer del cuello uterino.

Cervical cancer (CC) is the second most common cause of death from cancer among women worldwide and about 80% of the half of million new cases detected every year, occurs in less-developed countries. Human papillomavirus is an obligate factor for the development of CC, since some HPVtype are detected in 100% of CC. HPV16 and HPV18 are the most common viral types, accounting for about 50% and 15% of CC, respectively. HPV infection is the most common sexual transmitted infection, with an estimated prevalence of about 2-44% among sexually active young women. However, only a very small fraction of these infections evolve to CC (1-2 out of 1000), indicating that some other factors should be important in the evolution of the disease. Preventive vaccines against HPVs 16 and 18 have been developed, and in phase III clinical trials they have demonstrated 100% efficacy for prevention of persistent infection and high risk cervical squamous intraepithelial neoplasias positive for these HPV types, suggesting that these vaccines, if made widely available, will dramatically reduce the burden of CC.

Human papilloma virus 16-18 infection and cervical cancer in Mexico: A case-control study

Cervical cancer (CC) is one of the principal public health problems in Mexico. The national mortality rate due to CC was estimated at 21.8 per 100,000 among women over 15 years old during 1994. Despite this high incidence little is known in Mexico about the risk factors for CC. The objectives of the study were to evaluate the association between CC and HPV types 16 and 18 in women living in Mexico City. From august, 1990 to December, 1992, a case-control study was carried out in the metropolitan area of Mexico City. HPV 16-18 types were determined in a sample of 148 CC caes and 204 controls randomly selected from a sample frame representative of the metropolitan area of Mexico City. Sixty cases corresponded to in situ CC and 88 cases to the invasive phase. Determination of HPV 16 and 18 types was done by polymerase chain reaction using primers specific to E6/E7. Results showed that 48.3 percent of in situ CC cases and 48.8 percent of invasive CC cases were positive for HPV16 while only 13.2 percent were positive among the 204 controls. Association Between HPV 16 infection in the in situ cancer cases had an estimated odds ratio (OR) of 5.17 (95 percent CI 2.60 - 10.51). In the invasive cervical cancer cases, association between HPV 16 infection and invasive CC in this sample had an OR of 3.84 (95 percent CI 2.04 - 7.22). For the total sample, the estimated OR was 5.48 (95 percent CI 3.07-9.62). In the total sample, those women with a strong positive reaction to PCR were associated with a large increase in the risk, OR of 38.0(95 percent CI 8.66-167.1) The prevalence the HPV 18 was 6.7 percent, only observed in the invasive cervical cancer cases. At present there is general consensus that HPV is the principal causal agent in CC etiology. This study intends to contribute to the knowledge concerning the etiology of cervical cancer. However, it is necessary to consider that the single most effective tool in the reduction of mortality due to cervical cancer has been the Pap test. Secondary prevention has proven to be highly effective in other populations, and this should be viewed as a priority activity for all at-risk populations. Athough a vaccine for HPV may be avalilable in the near future its efficacy in primary prevention has yet to be demonstrated